We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.

GSK stock crumbled on Wednesday after vaccine sales tumbled, leading to a third-quarter miss. Revenue from RSV shot Arexvy ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker was hit by issues with access to the shots in the US.

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

UK pharma major GSK looked set to close Wednesday’s trading around 3% lower. The London-based drugmaker earlier presented its ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products. Read More on GB:GSK: GSK NewsMORE Related Stocks Indices ...

Shares of GSK fell over 3% following its third-quarter 2024 earnings, as investors reacted to underwhelming sales figures in ...